Artificial Heart Market Size & Growth Forecast 2027–2036, By Segments (Type, Therapy), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Artificial Heart Market size was valued at USD 3.8 billion in 2026 and is anticipated to grow at a 10.74% CAGR from 2027 to 2036, reaching USD 10.54 billion by 2036. The industry revenue for 2027 is assessed at USD 4.14 billion.
Get more details on this report
Request Free Sample ReportArtificial Heart Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 62.18% of the market in 2026, supported by advanced cardiac care infrastructure, specialized hospitals, experienced surgical teams, and consistent adoption of artificial heart therapies.
- Asia Pacific is expected to grow at a 12.54% CAGR, driven by expanding cardiovascular treatment access, improving hospital capabilities, rising patient demand, and wider availability of specialized cardiac procedures.
Segment Momentum
- LVADs accounted for a 74.3% share in 2026 due to their broad clinical adoption, established treatment role, and suitability for supporting advanced heart failure patients without complete heart replacement.
- Destination Therapy is expanding as more patients who are not eligible for heart transplantation require long-term mechanical circulatory support as a definitive treatment option.
Market Expansion Drivers
- Increasing donor heart shortage driving demand for artificial heart alternatives.
- Rising prevalence of heart failure and aging population increasing device adoption.
- Advancements in LVAD and total artificial heart technologies improving patient survival outcomes.
Leading Market Participants
- Key players in the artificial heart market include Abbott Laboratories (United States), SynCardia Systems, LLC (United States), CARMAT SA (France), ABIOMED, Inc. (United States), BiVACOR Inc. (United States), Jarvik Heart, Inc. (United States), Realheart AB (Sweden), LivaNova PLC (United Kingdom), Getinge AB (Sweden), Terumo Corporation (Japan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 3.8 billion
- 2027 Estimated Market Size: USD 4.14 billion.
- Projected Market Size: USD 10.54 billion by 2036
- Growth Forecast: 10.74% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: LVADs (Type) | Bridge To Transplant (Therapy)
- Emerging Opportunity Segment: Total Artificial Heart (Type) | Destination Therapy (Therapy)
Market Growth Drivers and Industry Trends
Increasing donor heart shortage driving demand for artificial heart alternatives
The persistent shortage of suitable donor organs is strengthening the artificial heart market as patients with advanced cardiac conditions face limited access to conventional transplantation. Artificial heart technologies can provide mechanical circulatory support for individuals who are not able to receive a donor heart immediately or who require an alternative treatment pathway. Growing pressure on healthcare systems to address unmet needs among patients with severe heart disease is encouraging continued development and clinical adoption of mechanical solutions that can sustain circulation when natural cardiac function is significantly compromised.
Rising prevalence of heart failure and aging population increasing device adoption
An aging population and the increasing prevalence of heart failure are contributing to the artificial heart market by expanding the population requiring advanced cardiac support. Older patients and individuals with progressive cardiovascular disease may experience declining heart function that cannot be adequately managed through conventional therapies alone, increasing the need for mechanical circulatory technologies. Improvements in patient selection, clinical management, and specialized cardiac care are also supporting broader consideration of artificial heart devices for patients with severe or end-stage heart failure.
Advancements in LVAD and total artificial heart technologies improving patient survival outcomes
Technological progress in left ventricular assist devices (LVADs) and total artificial heart systems is advancing the artificial heart market through improvements in device reliability, physiological support, and patient management. Modern systems are being developed to provide more effective circulatory assistance while addressing challenges associated with earlier generations of mechanical devices. Enhancements in pump design, control systems, biocompatibility, and device integration can improve treatment performance and support longer-term use in patients requiring mechanical cardiac assistance.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing donor heart shortage driving demand for artificial heart alternatives | 2.00% | High | North America, Europe | High | Near Term |
| Rising prevalence of heart failure and aging population increasing device adoption | 1.70% | High | North America, Asia Pacific | High | Mid Term |
| Advancements in LVAD and total artificial heart technologies improving patient survival outcomes | 1.40% | High | North America, Europe | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the artificial heart market at 62.18% in 2026, reflecting its advanced cardiovascular healthcare infrastructure, specialized medical expertise, and strong capabilities in complex cardiac procedures. The region benefits from established transplant and cardiac care systems, specialized treatment centers, and access to sophisticated medical technologies that support the development and clinical use of artificial heart solutions. Increasing attention to advanced treatment options for patients with severe heart conditions is encouraging continued investment in cardiac technologies. Strong healthcare research capabilities and an established ecosystem for specialized medical device adoption further support North America's leading market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing regional market, driven by improving cardiovascular care infrastructure, rising awareness of advanced cardiac therapies, and increasing access to specialized medical treatment. Healthcare systems across the region are expanding their capabilities for complex cardiac procedures, while investments in hospitals and specialized treatment facilities are improving access to advanced technologies. Growing demand for innovative solutions for patients with severe cardiac conditions is also encouraging broader adoption of mechanical circulatory support technologies. As healthcare modernization progresses and specialized cardiac services become more accessible, the region is creating increasingly favorable conditions for artificial heart market expansion.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Advanced Cardiac ProgramsGermany integrates artificial heart technologies within specialized cardiovascular centers supported by strong clinical expertise. German healthcare institutions prioritize long-term device performance, surgical precision, and coordinated patient management throughout advanced cardiac care.
France 🇫🇷
Research-Driven AdoptionFrance supports artificial heart deployment through clinical research initiatives and specialized cardiovascular treatment networks. French healthcare providers are focusing on evaluating innovative technologies while strengthening patient selection and post-implant monitoring practices.
Italy 🇮🇹
Cardiac Treatment IntegrationItaly continues integrating artificial heart technologies into advanced cardiac surgery and transplant programs. Italian hospitals are enhancing multidisciplinary care capabilities while supporting broader access to sophisticated mechanical circulatory support systems.
Japan 🇯🇵
Precision Medical EngineeringJapan advances artificial heart technologies through precision engineering and collaboration between healthcare providers and medical device developers. Japanese hospitals emphasize compact device design, patient safety, and reliable long-term circulatory support solutions.
South Korea 🇰🇷
Specialized Care ExpansionSouth Korea is strengthening artificial heart capabilities through investment in tertiary hospitals and advanced cardiac treatment programs. Medical institutions are expanding expertise in implant procedures and multidisciplinary patient care for severe heart failure cases.
United States 🇺🇸
Clinical Device InnovationThe U.S. artificial heart market benefits from advanced cardiovascular research, specialized hospitals, and strong medical device development. Healthcare providers in the U.S. are expanding adoption of mechanical circulatory support technologies for complex heart failure treatment pathways.
Segment Leadership and Growth Trends
Artificial Heart Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: LVADs (Largest Segment) vs Total Artificial Heart (Fastest-Growing Segment)
LVADs dominated the artificial heart market, accounting for a 74.3% share in 2026, supported by their established role in managing advanced heart failure and providing mechanical circulatory support for patients with limited cardiac function. Their clinical utility across bridge-to-transplant and longer-term treatment pathways, combined with established physician familiarity and improvements in device design, continues to reinforce demand. The segment also benefits from the growing need for advanced therapies for patients who are not adequately managed through conventional heart failure treatments.
Total artificial heart is emerging as the fastest-growing segment as advances in cardiac replacement technologies expand the scope of mechanical support beyond ventricular assistance. These systems can provide broader circulatory support for patients with severe or complex cardiac conditions, creating opportunities where conventional ventricular assistance may be insufficient. Continued innovation aimed at improving device functionality, patient mobility, and treatment outcomes is supporting greater clinical interest in complete heart replacement approaches.
Therapy Segment Analysis: Bridge To Transplant (Largest Segment) vs Destination Therapy (Fastest-Growing Segment)
The bridge to transplant segment held the largest share of the artificial heart market in 2026, reflecting the important role of mechanical circulatory support in stabilizing eligible patients while they await heart transplantation. LVAD-based support can help maintain cardiac function and improve patients' ability to remain viable candidates for transplantation, making this therapy particularly relevant amid the need to manage advanced heart failure during the transplant pathway. Established clinical protocols and the use of mechanical support as an interim treatment further sustain adoption.
Destination therapy is gaining momentum as improvements in device reliability and patient management expand the use of long-term mechanical circulatory support for individuals who are not suitable candidates for transplantation. The approach provides an alternative pathway for managing advanced heart failure over an extended period, increasing its relevance as clinicians seek durable treatment options. Progress in device technology, remote monitoring, and post-implantation care is also helping improve the practicality of long-term therapy.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | LVADs, Heart-lung Machine, Total Artificial Heart | LVADs | Total Artificial Heart |
| Therapy | Bridge To Transplant, Destination Therapy, Bridge To Decision, Others | Bridge To Transplant | Destination Therapy |
Competitive Landscape and Market Positioning
Top players in the artificial heart market:
1. Abbott Laboratories (United States)
2. SynCardia Systems LLC (United States)
3. CARMAT SA (France)
4. ABIOMED Inc. (United States)
5. BiVACOR Inc. (United States)
6. Jarvik Heart Inc. (United States)
7. Realheart AB (Sweden)
8. LivaNova PLC (United Kingdom)
9. Getinge AB (Sweden)
10. Terumo Corporation (Japan)
Advances in biomedical engineering are improving mechanical circulatory support solutions for critical care patients. Miniaturization and biocompatibility enhancements are driving next-generation device development. The artificial heart market is progressing with increasing focus on life-extending therapeutic innovations and patient-specific solutions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| SynCardia Systems LLC (United States) | |||||||
| CARMAT SA (France) | |||||||
| ABIOMED Inc. (United States) | |||||||
| BiVACOR Inc. (United States) | |||||||
| Jarvik Heart Inc. (United States) | |||||||
| Realheart AB (Sweden) | |||||||
| LivaNova PLC (United Kingdom) | |||||||
| Getinge AB (Sweden) | |||||||
| Terumo Corporation (Japan). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| BiVACOR | Nov-25 | BiVACOR received U.S. FDA Breakthrough Device Designation for its titanium-based Total Artificial Heart, a significant regulatory milestone that accelerates the development and clinical review process for its biventricular heart failure technology. This recognition underscores the device's potential as a durable, long-term mechanical circulatory support solution for patients awaiting donor heart transplants. |
| Edwards Lifesciences | Nov-25 | The U.S. Federal Trade Commission successfully blocked Edwards Lifesciences' proposed $945 million acquisition of JenaValve Technology. The court’s preliminary injunction, citing concerns over reduced competition in the TAVR-AR device market, creates strategic uncertainty for Edwards and highlights the intensifying regulatory scrutiny surrounding pipeline acquisitions in the specialized cardiac medical device industry. |
| BiVACOR | Oct-25 | A patient implanted with the BiVACOR titanium Total Artificial Heart successfully maintained circulatory support for 105 days before receiving a donor heart transplant. This clinical milestone, part of the U.S. FDA Early Feasibility Study, validates the safety, performance, and durability of the device as an effective bridge-to-transplant therapy for end-stage heart failure. |
| Evaheart Medical Equipment | Oct-25 | Evaheart launched the EVA-Pulsar ventricular assist device, marking its second artificial heart product and the fifth domestically developed technology of its kind in China. This expansion strengthens the company's cardiovascular device portfolio and reflects the growing maturity of the Chinese market in developing sophisticated mechanical circulatory support systems for advanced heart failure. |
| Edwards Lifesciences | Oct-25 | Edwards Lifesciences expanded its structural heart portfolio through a series of strategic acquisitions and investments totaling over $1.5 billion. The portfolio additions, including companies such as Endotronix, Innovalve, and Affluent Medical, demonstrate a significant capital deployment strategy aimed at securing early-stage technologies and consolidating market positioning within the broader cardiovascular device ecosystem. |
| BiVACOR | Feb-24 | BiVACOR secured a USD 13 million grant from the Australian Government’s Medical Research Future Fund to support its Total Artificial Heart program. This investment provides essential financial backing for the ongoing research, development, and clinical evaluation of the device as a long-term therapy option for patients facing severe, end-stage biventricular heart failure. |
| CARMAT | Dec-23 | CARMAT successfully performed its first implant of the Aeson total artificial heart for a patient suffering from a cardiac tumor. As one of the few commercially available total artificial hearts, the device represents a critical therapeutic alternative for patients with advanced biventricular heart failure, demonstrating the company's progress in clinical implementation within the European market. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Artificial Heart Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Implant Duration | Short-Term Support, Intermediate-Term Support, Long-Term Support |
| Patient Age Group | Pediatric Patients, Adult Patients, Geriatric Patients |
| Care Setting | Transplant Centers, Specialized Cardiac Hospitals, General Hospitals |
Artificial Heart Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Advanced Cardiac Assist Technology Adoption Study |
|
| Transplant Alternative Strategy Assessment |
|
| Artificial Heart Commercialization Pathway |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the artificial heart market?
What is the projected value of the artificial heart industry by 2036?
How is donor heart scarcity influencing the timing and adoption of artificial heart solutions in clinical care pathways?
How are aging-related heart failure prevalence and device advancements shaping clinical acceptance of artificial heart systems?
Why do LVADs dominate the artificial heart market?
What is driving the growth of Destination Therapy in the artificial heart market?
Why is North America the leading region in the artificial heart market?
What is fueling artificial heart market growth in Asia Pacific?
Which companies are driving growth in the artificial heart landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization